Ponatinib: Difference between revisions
m →Clinical trials: pivotal phase II |
Carlo Banez (talk | contribs) - link to FDA information, infobox upgraded from Chembox to Drugbox |
||
| Line 1: | Line 1: | ||
{{ |
{{Drugbox |
||
| drug_name = |
|||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| ⚫ | |||
| ⚫ | |||
| |
| image = Ponatinib.svg |
||
| alt = |
|||
| ImageSize = 200px |
|||
| caption = |
|||
| ⚫ | |||
| ⚫ | |||
<!-- Clinical data --> |
|||
| Section1 = {{Chembox Identifiers |
|||
| tradename = Iclusig |
|||
| ⚫ | |||
| Drugs.com = |
|||
| CASNo_Ref = {{cascite|correct|CAS}} |
|||
| |
| MedlinePlus = |
||
| licence_US = Ponatinib |
|||
| ⚫ | |||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|||
| ⚫ | |||
| pregnancy_US = D |
|||
| ⚫ | |||
| pregnancy_category= |
|||
| InChI = InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39) |
|||
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|||
}} |
|||
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
|||
| Section2 = {{Chembox Properties |
|||
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
|||
| ⚫ | |||
| |
| legal_US = Rx-only |
||
| |
| legal_status = |
||
| routes_of_administration = Oral |
|||
| MeltingPt = |
|||
| BoilingPt = |
|||
<!-- Pharmacokinetic data --> |
|||
| Solubility = |
|||
| bioavailability = |
|||
}} |
|||
| protein_bound = |
|||
| Section3 = {{Chembox Hazards |
|||
| metabolism = |
|||
| MainHazards = |
|||
| elimination_half-life = |
|||
| FlashPt = |
|||
| excretion = |
|||
| Autoignition = |
|||
}} |
|||
<!-- Identifiers --> |
|||
| ⚫ | |||
| ATC_prefix = <!-- 'none' if uncategorised --> |
|||
| ATC_suffix = |
|||
| PubChem = |
|||
| DrugBank = |
|||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
<!-- Chemical data --> |
|||
| chemical_formula = |
|||
| ⚫ | |||
| molecular_weight = 532.56 g mol |
|||
| ⚫ | |||
}} |
}} |
||
Revision as of 16:03, 18 December 2012
 | |
| Clinical data | |
|---|---|
| Trade names | Iclusig |
| Other names | AP24534 |
| License data | |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C29H27F3N6O |
| Molar mass | 532.56 g mol g·mol−1 |
| 3D model (JSmol) | |
| |
Ponatinib (Iclusig, previously AP24534) is an FDA approved oral drug candidate for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor.[1] Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.[2]
Approvals and indications
Ponatinib was approved by the US FDA on December 14, 2012 for patients with resistant or intolerant CML and Ph+ ALL, based on results of the PACE phase II trial reported days earlier at the annual ASH meeting.[3] Because the approval was under the FDA's accelerated approval program the applicant will be required to carry out additional studies.
Clinical trials
The PACE (Ponatinb Ph+ ALL and CML Evaluation) pivotal phase II trial started enrolling patients in September 2010 and is designed to provide definitive clinical data for regulatory approval in this setting. ARIAD Pharmaceuticals, the company that is developing ponatinib, said it expects full enrollment of the PACE trial in the third quarter of 2011.[citation needed] Good results were reported in Dec 2012.[3][4]
At the 2010 annual meeting of the American Society of Hematology, ARIAD announced from a Phase I study of ponatinib in patients with resistant and refractory chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). The study demonstrated that in chronic-phase CML patients treated with ponatinib, 66 percent of patients in the trial achieved a major cytogenetic response, including 100 percent of patients who also had a T315I mutation.[citation needed]
Mechanism
The primary target for ponatinib is BCR-ABL, an abnormal tyrosine kinase that is the hallmark of CML and Ph+ ALL. CML is characterized by an excessive and unregulated production of white blood cells by the bone marrow due to a genetic abnormality that produces the BCR-ABL protein. After a chronic phase of production of too many white blood cells, CML typically evolves to more aggressive phases such as accelerated or blast crisis. Ph+ ALL is a subtype of acute lymphoblastic leukemia that carries the Ph+ chromosome that produces BCR-ABL. It has a more aggressive course than CML and is often treated with a combination of chemotherapy and tyrosine kinase inhibitors. Because both of these diseases express the BCR-ABL protein, this would render them potentially susceptible to treatment with ponatinib. BCR-ABL is detected in 95% of patients with CML. Patients with CML currently receive front line therapies nilotinib and/or dasatinib though 22-33% of patients discontinue therapy by two years due to adverse events, treatment failure and other causes.[citation needed]
Design rational
Ponatinib was designed using ARIAD’s computational and structure-based drug design platform to inhibit the enzymatic activity of BCR-ABL with very high potency and broad specificity. Ponatinib was intended to target not only native BCR-ABL, but also its isoforms that carry mutations that confer resistance to treatment with existing tyrosine kinase inhibitors, including especially the T315I mutation for which no effective therapy exists.[5]
See also
References
- ^ {{cite journal | pmid = 20513156 | year = 2010 | last1 = Huang | first1 = WS | last2 = Metcalf | first2 = CA | last3 = Sundaramoorthi | first3 = R | last4 = Wang | first4 = Y | last5 = Zou | first5 = D | last6 = Thomas | first6 = RM | last7 = Zhu | first7 = X | last8 = Cai | first8 = L | last9 = Wen | first9 = D | title = Discovery of 3-2-(imidazo1,2-bpyridazin-3-yl)ethynyl-4-methyl-N-{4-(4-methylpiperazin-1-yl)methyl-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant | volume = 53 | issue = 12 | pages = 4701–19 | doi = 10.1021/jm100395q | journal = Journal of Medical Chemistry}}
- ^ O'Hare, T; Shakespeare, WC; Zhu, X; Eide, CA; Rivera, VM; Wang, F; Adrian, LT; Zhou, T; Huang, WS (2009). "AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance". Cancer Cell. 16 (5): 401–12. doi:10.1016/j.ccr.2009.09.028. PMC 2804470. PMID 19878872.
- ^ a b Ponatinib Wins Early FDA Nod
- ^ Ponatinib Retains Luster in Leukemia. Dec 2012
- ^ Zhou, Tianjun; Commodore, Lois; Huang, Wei-Sheng; Wang, Yihan; Thomas, Mathew; Keats, Jeff; Xu, Qihong; Rivera, Victor M.; Shakespeare, William C. (2011). "Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance". Chem Biol Drug Des. 77 (1): 1–11. doi:10.1111/j.1747-0285.2010.01054.x. PMID 21118377.
{{cite journal}}: Unknown parameter|month=ignored (help)